Pyrexar Medical Acquires Hyperthermia Assets of BSD Medical

— Promising Cancer Treatment Technology Now Under New Leadership

SALT LAKE CITY, April 3, 2015 /PRNewswire/ — Pyrexar Medical begins operations today after completing the acquisition of hyperthermia assets held by Perseon (NASDAQ:PRSN), formerly BSD Medical (NASDAQ:BSDM). This acquisition includes substantially all hyperthermia assets, products, services and related intellectual property.

BSD-500 Hyperthermia System

BSD-500 Hyperthermia System

Photo – http://photos.prnewswire.com/prnh/20150402/196321

Medical device industry veteran Mark Falkowski has been named Chief Executive Officer bringing to Pyrexar more than 30 years of successful executive leadership experience with prominent medical companies like GE Healthcare, Imatron, Carestream and OEC/Diasonics.

Mr. Falkowski recruited seasoned capital equipment executives, A. Robert Depalma, Brian Chard, Rex Harmon and Drew Wilkens. Also joining, former Perseon employees Paul Turner, Ray Lauritzen, Richard Faux, Dennis Bradley and a group of highly trained system design, production and customer support team members directly associated with the hyperthermia product line. The new group’s goal is to build a sales and customer focused company.

Mr. Falkowski said: “New minimally invasive treatment technologies are vital to winning the fight against cancer and I look forward to taking an active part in bringing this important cancer fighting medical technology to market.”

Pyrexar will be presenting and exhibiting at the upcoming Society for Thermal Medicine Annual Meeting in Orlando, FL (April 14-17, 2015).

ABOUT PYREXAR MEDICAL:

With the acquisition of BSD Medical assets, Pyrexar Medical takes its place as pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity of healthy tissues.

Multi-center clinical trials in the US, Europe and Asia over the past 30 years document dramatic improvement in survival rates when PYREXAR HT is combined with radiotherapy in the treatment of chest wall recurrences after breast cancer, locally advanced cervical cancer, high risk soft tissue sarcoma, melanoma and other malignancies.

Pyrexar Medical is based in Salt Lake City, UT, USA. For more information please visit our web page at: pyrexar.com

Pyrexar Medical Media Contact:
Drew Wilkens
VP of Digital Marketing
+1-844-797-3927
drew.wilkens@pyrexar.com

Photo – http://photos.prnasia.com/prnh/20150403/8521502127

Biosafe Goes Direct in Brazil, Acquiring Its Local Distributor

EYSINS, Switzerland, March 30, 2015 /PRNewswire/ — After a successful partnership of 10 years with its local distributor ACTS do Brasil Ltda., effective immediately Biosafe has acquired all ACTS’ Biosafe-related business, which has been spun off into a separate operating entity, Biosafe Brasil Distribuidora Ltda. Terms have not been disclosed.

This move will allow Biosafe to offer an extended range of benefits to customers in Brazil, including direct product support and service.

Today most public and private cord blood banks throughout the country already process with Biosafe’s proprietary Sepax technology, which is also used by a number of customers for regenerative medicine applications.

Olivier Waridel, CEO of the Biosafe Group, commented: “We firmly believe in the potential of the Brazilian market and this acquisition will further expand our  business  in our core markets of stem cell banking, regenerative medicine and bioprocessing. We look forward to strengthening our relationship with existing and future customers, and to assisting them with their development.”

Elsewhere in Latin America, Biosafe products are sold through distributors in Mexico, Argentina, Colombia and Chile. Biosafe plans to extend the network to additional countries in the near future.

About the Biosafe Group   

Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and Sao Paulo) and is present in more than 50 countries, either directly or through distributors.

For further information:

Christopher Bolton
CFO
Biosafe Group SA
+41-22-365-27-27
christopher.bolton@biosafe.ch
http://www.biosafe.ch

Pegasus diversifies into advertising business and publication of high-end magazine “Platinum of UnionPay”

HONG KONG, March 9, 2015 /PRNewswire/ — The Board of Directors of Pegasus Entertainment Holdings Limited (“Pegasus” or the “Company”, stock code: 1326) announced on 6 March 2015 that the Company entered into a conditional agreement on the same date, to acquire the entire interest in Chili Advertising & Promotions Limited (the “Target Company”), which includes an indirect 70% interest in Chili Platinum Advertising and Magazine Publishing Limited (“Chili Platinum”), at a total consideration of HK$68.0 million. Chili Platinum is a company principally engaged in the publication of the luxury lifestyle magazine “Platinum of UnionPay”.

The consideration represents a discount of approximately 18% to the preliminary valuation of the Target Group issued by an independent valuer, which is not less than HK$82.6 million; and will be settled partly by cash and partly by the Company’s issue of consideration shares at HK$1.26 per share.

“Platinum of UnionPay” is a magazine which will be provided on a complementary basis to selected premium level cardholders of UnionPay and the target audience group covers the high-end consumer market in mainland China, Hong Kong and Macau. The magazine features a wide range of contents on luxurious lifestyle related products and services, ranging from fashion, jewellery, entertainment, food and restaurants, leisure, to art and culture. The magazine is currently distributed to various high-end private clubs, golf clubs and hotels, and also with selected contents distributed online through a number of digital media, in order to successfully capture the maximum number of targeted readership base.

The Directors are optimistic about the future development of printed and digital media advertising in the China market. In view of the growing consumption of luxury products and services in China, more international luxury brands are strengthening their foothold in China hence encouraging the advertising market for high-end goods. Given the principal target audience of “Platinum of UnionPay” magazines are high net worth individuals and other elite groups in China, who are the selected premium level cardholders of UnionPay with high disposable income, the Company is of the view that this acquisition is able to offer Pegasus the access to an established and considerable high-spending readership base for marketing purposes and therefore enables it to secure a strong competitive advantage within the industry.

Mr. Wong Pak Ming, Chairman of Pegasus, says, “By diversifying the Company’s platform into printed and digital media business, we will create synergy with our existing core business of film production and distribution by providing an additional solid marketing channel in China. That will also give Pegasus a high degree of control on the marketing campaign of our productions and to further expand our potential audiences to the high-end consumer market of China. Since the Target Company has extensive experience in the provision of film advertising and promotion services, we believe this acquisition will allow us to develop a professional in-house advertising and promotion team, which will benefit Pegasus in terms of providing flexibility to formulate and fine-tune our advertising and promotion strategies. This is an important step towards our expansion into a diversified cultural business.”

About Pegasus Entertainment Holdings Limited

Pegasus Entertainment Holdings Limited, as a diversified cultural business group, is principally engaged in the business of films and television series production, distribution, licensing of film rights, film exhibition and post-production.

About UnionPay

According to its corporate website, UnionPay, which is headquartered in China, has about 400 associate members worldwide, with its cards accepted in 150 countries and regions outside China. UnionPay has issued over 4.6 billion bank cards globally. According to its transaction data released in January 2015, UnionPay’s global network processed transactions with a total volume of RMB41 trillion in 2014, representing a year-on-year increase of 27.3%.

For further details, please refer to the announcement on HKEX website:

http://www.hkexnews.hk/listedco/listconews/SEHK/2015/0306/LTN20150306793.pdf

Making the Old New Again — Blazblue Takes a Bold Approach

GUANGZHOU, China, March 4, 2015 /PRNewswire/ — 37Games, a global browser and mobile game publisher and developer, recently acquired the publish rights of Blazblue Revolution Reburning (BBRR) of Mainland China. The game’s idea is based on a worldwide famous fighting game title Blazblue, which is originally developed by Arc System Works (Yokohama, Japan).

In Mainland China, there are two directions in which developers can choose to take upon acquiring licenses from outside firms. The first option is to simply incorporate the characters, story lines, and artwork into an existing game engine. Using the framework from existing games can keep costs low for the developer and is considerably less risky than using an all-new game engine or design. Players will already be familiar with the mechanics of the game, so it is basically a simple matter of re-skinning the game and telling a different story.

A more risky approach some developers would take is to acquire the related licenses and then develop a completely new game from the ground up.

Blazblue Revolution Reburning (BBRR), a Japanese style fighting game for the mobile market, is a recent example of a game that was built from the ground up using purchased license.

91Act, a mobile game developer, get the related licenses from Arc System Works and re-developed the game from zero, then grant the Operation Right of BBRR in Mainland to 37Games.

So far, the more risky approach seems to be paying off. BBRR has already been nominated as the “Most Anticipated Game” by Baidu Mobile Games. BBRR has even garnered some celebrity attention. Two well-known celebrities have agreed to fight in the game. The loser will have to embarrassedly support a garment according to the winner’s choice.

As China is poised to be the world’s largest entertainment market, the future seems to be bright for those foreign firms who are willing to share their licenses with capable developers and publishers. The number of current online users in China surpasses previous records and the surge is expected continue in coming years. It is likely for more to seize this opportunity looking ahead.

Denovo Biopharma Licenses Late-Stage Neuroscience Drug From Lilly For Development As A Personalized Medicine

– Potentially first biomarker-guided schizophrenia therapeutic

– Novel mechanism of action with improved safety profile

– Denovo’s second late-stage asset acquired in the past 6 months

SAN DIEGO, March 3, 2015 /PRNewswire/ — Denovo Biopharma, LLC, today announced that it has exclusively licensed Pomaglumetad Methionil (mGlu2/3 receptor agonist), a late-stage neuroscience drug, from Eli Lilly and Company (NYSE:  LLY). Denovo gains all rights to develop, manufacture and commercialize pomaglumetad globally, including transfer of all intellectual property and other rights, data, and information. Lilly has an option to re-acquire pomaglumetad upon a successful clinical trial, for predetermined undisclosed financial terms. 

Logo – http://photos.prnewswire.com/prnh/20140820/138306

Pomaglumetad was primarily developed and tested in schizophrenia, including in Phase 2 and Phase 3 clinical trials. Predefined sub-population analysis and post-hoc analysis across multiple studies identified a meaningful subset of patients who showed significantly improved outcomes, although pomaglumetad did not meet the primary endpoint in the intent-to-treat population in Phase 3 studies.  Denovo will use its proprietary platform to identify genetic biomarkers as a companion diagnostic to screen for appropriate patient subsets in future clinical trials and eventual commercialization.

“Denovo continues to acquire late-stage medicines to successfully develop with its integrated companion diagnostic and therapeutic development approach, including the acquisition of enzastaurin, a late-stage oncology therapeutic, in September 2014.  Lilly is a world leader in the development of neuroscience drugs and will be a valuable collaborator in pomaglumetad’s continued development,” said Michael F. Haller, Ph.D., Denovo Biopharma’s Chief Operating Officer.

About Pomaglumetad Methionil

Pomaglumetad Methionil (DB103, formerly LY2140023) is a novel glutamatergic-based investigational agent that does not interact with select central nervous system receptors that are thought to be responsible for many of the potential adverse events associated with some antipsychotic drugs which could compromise the treatment of patients with schizophrenia. 

About Denovo Biopharma

Denovo Biopharma is a privately-held biotechnology company that provides novel and proprietary biomarker approaches to personalized drug development, including re-evaluating medicines that have failed in general patient populations and studying them in the original indication in biomarker-selected sub-populations. The company offers the first platform and algorithm for de novo genomic biomarker discovery using archived clinical samples. This technology may be especially useful for compounds with suboptimal late-stage trial results.  By identifying biomarkers correlated with patients’ responses to drug candidates retrospectively, Denovo enables the design and execution of follow-on clinical trials in targeted patient populations with increased likelihood of success. For additional information please visit www.denovobiopharma.com.

Contact:
Michael Haller, Chief Operating Officer
Denovo Biopharma, LLC
(858) 876-4012
mhaller@denovobiopharma.com

Nirvana Asia Ltd Acquires Tomb Design and Construction Business

— Vertical Integration to Strengthen Capabilities and Pursue Diversification in Death Care Service Sector

HONG KONG, March 3, 2015 /PRNewswire/ — Nirvana Asia Ltd (“Nirvana Asia” or the “Company”, together with its subsidiaries, the “Group”, SEHK stock code: 1438) is pleased to announce that a wholly-owned subsidiary of the Group has acquired the tomb design and construction business from the tomb contractors at the six memorial parks of the Group and throughout Malaysia at an aggregate consideration of RM15,000,000 (equivalent to approximately US$4,162,500).

Pursuant to the Sale and Purchase Agreement, WFS Memorial Tomb Management Sdn. Bhd. (the “Vendor”), and Wong Chen Hoong and Wang Siew Yuen (collectively, the “Guarantors”) have agreed to provide a guaranteed audited net profit after tax for the acquired business in the amount of RM4,000,000 (equivalent to approximately US$1,110,000), RM5,000,000 (equivalent to approximately US$1,387,500) and RM5,500,000 (equivalent to approximately US$1,526,250), respectively, for the financial period of 10 months ending 31 December 2015, and the financial years ending 31 December 2016 and 2017.

The Directors believe that this downstream acquisition would allow the Group to strengthen its capabilities in the death care service sector while pursuing diversified development along the industry value chain. Furthermore, the Directors are of the view that this acquisition would help create synergies with the Group’s existing death care service business and may help enhance the gross profit margin of the Group’s tomb design and construction segment.

In connection with the acquisition, each of the six subsidiaries of the Group with operations at the relevant memorial parks has agreed to allot and issue one irredeemable non-convertible “Class A” preference share with a nominal value of RM1 (collectively, the “Preference Shares”) to the Guarantors. Such Preference Shares may entitle the Guarantors to a fixed, non-cumulative cash dividend of 5% of the nominal value of the Preference Shares and a special dividend representing 25% of the audited net profit after tax of the acquired business.

The consideration represents four times the profit guarantee for the acquired business for the financial year ending 31 December 2016 less 25% thereon to which the Guarantors may be entitled pursuant to their holding of the Preference Shares.

Dato’ Kong Hon Kong, an Executive Director, the Managing Director and the Chief Executive Officer of Nirvana Asia said, “This acquisition presents an attractive opportunity for the Group to strengthen our death care service capabilities in terms of tomb design and construction. We will continue to seize various opportunities with a view to further solidifying our leading position in the industry and delivering satisfactory returns to our investors.”

For further information, please contact:
iPR Ogilvy & Mather
Natalie Tam / Charis Yau / Juliana Li / Candy Tam
Tel: (852) 2136 6182 / 2136 6183 / 2169 0467 / 3920 7626
Fax: (852) 3170 6606
Email: nirvana@iprogilvy.com

About Nirvana Asia

Nirvana Asia is the largest integrated death care service provider in Asia, in terms of contract sales, revenue and land bank in 2013. The Company offers burial and funeral services and products on both as-need and pre-need basis, strategically targeting the premium segment of the death care services market. In 2013, Nirvana Asia is the largest death care service provider in Malaysia and the largest burial service provider. Currently, the Company offers death care products and services through a network of 10 cemeteries, 12 columbarium facilities, six on-site crematoria and two funeral homes in Malaysia, Indonesia and Singapore. In February 2015, the Company has also entered into a binding cooperation agreement with Huizhou Longyan and marked the first step tapping into the PRC market.

Omnicell, Inc. Signs Agreement to Acquire Germany-based Pharmacy Automation Provider, MACH4 Pharma Systems

— Addition of Robotic Pharmacy Automation Solutions for Hospital and Retail Pharmacies to Expand Omnicell International Growth

MOUNTAIN VIEW, Calif., Feb. 27, 2015 /PRNewswire/ — Omnicell, Inc. (OMCL), a leading provider of medication and supply management solutions to healthcare systems and pharmacies, today announced that it has signed an agreement to purchase MACH4 Pharma Systems, based in Bochum, Germany. The closing of the acquisition is subject to certain closing conditions set forth in the definitive purchase agreement. When and if the acquisition is finalized, the combination of Omnicell and MACH4 will create a comprehensive automated medication management offering for hospital and retail pharmacies throughout Europe and emerging markets internationally.

Logo – http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a

MACH4 Pharma Systems is a provider of highly automated medication management systems to a base of over 1,000 retail and hospital pharmacy customers primarily in Europe, with additional installations in China and the Middle East.

MACH4’s modular robotic solutions for dispensing medications in original manufacturers’ packages enable the company to serve the needs of a broad spectrum of pharmacy customers, from large hospital systems to local retailers. The flexible design of MACH4 systems provides both the chaotic method of storage and retrieval that optimizes for high capacity storage in the minimum amount of physical space, and the channel method of storage and retrieval that optimizes for speed of delivery. MACH4 systems are uniquely configurable to suit each specific customer’s needs. MACH4 systems complement unique capabilities of Omnicell dispensing systems to handle medications in original manufacturers’ packages. Omnicell expects to realize expanded market opportunities as each company’s solutions are introduced to the other’s customer base.

“Omnicell is committed to providing a complete set of pharmacy automation solutions that increases efficiencies and promotes patient safety in hospital, long term care and retail settings, and to taking our global presence to a new level,” said Randall Lipps, chairman, president and CEO of Omnicell. “With MACH4, the expanded Omnicell portfolio will include innovative solutions that span robotic medication management systems, automated dispensing cabinets and medication adherence technology to meet the unique demands of our growing base of customers worldwide to provide services across the continuum of care.”

The MACH4 Pharma Systems acquisition is a continuation of Omnicell’s expansion into markets outside the United States, including the recent purchase of UK-based medication adherence packaging leader Surgichem Limited. Omnicell expects to accelerate its international growth by integrating MACH4’s high-volume medication management technology with Omnicell automated dispensing systems in the markets Omnicell presently serves, while also expanding its opportunities through MACH4’s direct presence in Germany and France.

“I expect that joining the Omnicell family will be welcome news to our customers who have come to trust MACH4’s mission to make medication management as efficient as possible in any setting,” said Holger Wallat, co-founder and CEO of MACH4. “Omnicell and MACH4 share that passion with very complementary solutions. For example, our box and blister pack management customers should benefit from Omnicell automatic dispensing cabinets that are uniquely capable of managing hospital workflows for drugs in the manufacturer’s original packaging,” he said.

Omnicell expects the acquisition to close in the first or second quarter of 2015, provided certain closing conditions are satisfied. Assuming an April 1, 2015 close, Omnicell expects 2015 revenue contribution from MACH4 will be between $12 and $15 million and Non-GAAP earnings per share dilution of approximately $0.04 as the companies are integrated. Omnicell expects the acquisition to become accretive during 2016. As a result, Omnicell financial guidance for 2015 is adjusted to include the expected results from MACH4 following the acquisition. Revenue for 2015 was previously expected to be between $480 and $490 million and is now expected to be between $492 and $505 million, an increase of 12% to 15% over 2014. Non-GAAP earnings per share were previously expected to be between $1.35 and $1.40 and are now expected to be between $1.31 and $1.36. Omnicell previously expected 2015 product bookings to be between $390 and $405 million and now expects product bookings between $398 and $416 million with the inclusion of MACH4.

About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new efficiencies to improve patient care, anywhere it is delivered. Omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum  from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home.

More than 3,000 customers worldwide have utilized Omnicell Automation and Analytics solutions to increase operational efficiency, reduce errors, deliver actionable intelligence and improve patient safety. Omnicell Medication Adherence solutions, including its MTS Medication Technologies brand, provide innovative medication adherence packaging solutions to help reduce costly hospital readmissions. In addition, these solutions enable approximately 6,000 institutional and retail pharmacies worldwide to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.

For more information about Omnicell, Inc. please visit www.omnicell.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to the anticipated consummation of the acquisition of MACH4 Pharma Systems and the benefits thereof, including Omnicell’s expectations of future revenue, bookings and earnings, anticipated integration costs, and the combined company’s ability to help reduce medication errors and lower healthcare costs and other statements that are not historical facts. These forward-looking statements are based on Omnicell’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Omnicell’s ability to complete the acquisition on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of closing conditions, including, but not limited to risks associated with business combination transactions, such as the risk that acquired business will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; risks related to future opportunities and plans for the combined company, including the reaction of the combined company’s customers and potential customers, the perceived complementary nature of the combined company’s products and solutions, uncertainty of the expected financial performance, market opportunities and results of the combined company following completion of the proposed acquisition; and the possibility that if Omnicell does not achieve the perceived benefits of the proposed acquisition of MACH4 as rapidly or to the extent anticipated by financial analysts or investors, the market price of Omnicell stock could decline; as well as other risks related Omnicell’s business, and those other risks detailed from time to time under the caption “Risk Factors” and elsewhere in Omnicell’s SEC filings and reports, including in the Annual Report on Form 10-K for the year ended December 31, 2013 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Omnicell undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

OMCL – G

Samsonite Strengthens its Global Retail Presence with Acquisition of Travel Retail Specialist Rolling Luggage

HONG KONG, Feb. 17, 2015 /PRNewswire/ — Samsonite International S.A. (“Samsonite” or the “Company”) today announced that it has completed the acquisition of Rolling Luggage, one of the world’s leading airport retailers of branded luggage and travel products for business, fashion, adventure and leisure travel, from the Rcapital owned Tie Rack Retail Group for a cash consideration of GBP 15.75 million. The acquisition is part of Samsonite’s ongoing strategy to enhance and strengthen its global multi-brand retail platform, as well as gain share in the large and growing travel retail market.

“Rolling Luggage is an exciting new addition to Samsonite and is unlike any of our previous acquisitions,” said Ramesh Tainwala, Chief Executive Officer of Samsonite. “It immediately allows us to expand our footprint in the travel retail sector, an area that we see great potential for further growth. With international tourist arrivals worldwide expected to almost double by 2030, reaching 1.8 billion[1], and international tourism sales growing by more than 12% a year since 2009[2], airport retail will continue to evolve as airports become shopping destinations in their own right.”

Mr. Tainwala continued, “With the established retail and brand presence that Rolling Luggage has across some of the world’s highest-traffic airports, we see this acquisition very much as a strategic opportunity to strengthen our multi-brand retail platform, increase visibility for Samsonite products among our target consumers and drive sales by offering better product assortment within an improved in-store experience.”

Alex Willson, Managing Director of Rolling Luggage, said, “We are thrilled to be joining Samsonite. Their considerable experience in the travel luggage industry and our passion about travel are a perfect match. We will work together to continue to ensure that we provide our consumers with a diverse and compelling product offering.”

Headquartered in the UK, Rolling Luggage operates 36 airport retail locations in the UK, Europe, and Asia Pacific, including prime retail locations in Heathrow, Sydney, Melbourne, Frankfurt and Hong Kong airports. Rolling Luggage offers world class products which combine functionality with style that travellers can trust. Historically part of the Tie Rack Retail Group, Rolling Luggage became a standalone business following completion of an internal restructuring in April 2014.

Rolling Luggage recorded net sales of GBP 26.7 million for the year ended January 31, 2015, an increase of 11.3% from GBP 24.0 million the previous year.

About Samsonite

Samsonite International S.A. (together with its consolidated subsidiaries, the “Group”) is the world’s largest travel luggage company, with a heritage dating back more than 100 years. The Group is principally engaged in the design, manufacture, sourcing and distribution of luggage, business and computer bags, outdoor and casual bags, and travel accessories throughout the world, primarily under the Samsonite®, American Tourister®, Hartmann®, High Sierra®, Gregory®, Speck® and Lipault® brand names and other owned and licensed brand names. The Group’s core brand, Samsonite, is one of the most well-known travel luggage brands in the world.

For more information, please contact:

Samsonite International S.A.
William Yue
Tel: +85224222611
Email: william.yue@samsonite.com

 

Asia: Artemis Associates

Vanita Sehgal

Tel: +85228613227

Mob: +85291034626

Email: vanita.sehgal@artemisassociates.com  

 

Jonathan Yang

Tel: +85228613234

Mob: +85263736676

Email: jonathan.yang@artemisassociates.com      

Europe: Newgate Communications             
Jonathan Clare

Tel: +442076806500

Clotilde Gros

Tel: +442076806522

Mob: +447899790749

Georgia Lewis

Tel: +442076806528

Mob: +447718619905

Email: samsonite@newgatecomms.com

[1] UNWTO
[2] http://www2.deloitte.com/content/dam/Deloitte/global/Documents/Consumer-Business/gx-cb-global-powers-of-retailing.pdf